Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS or Parkinson’s disease (PD) . The observed metabolic homeostasis may be neuroprotective.
CNM-Au8 is a suspension of clean-surfaced, faceted, gold nanocrystals that promotes remyelination and neuroprotection by catalysing nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP) production and by reducing oxidative stress. Treatment effects are evaluated using high-resolution 31P-magnetic resonance spectroscopy (31P-MRS). With this quantitative technique, bioenergetic metabolites can be monitored, as well as phospholipid and myelin precursors.
Preliminary target engagement data from 2 ongoing open-label imaging trials were presented: REPAIR-MS and REPAIR-PD. Treatment consisted of CNM-Au8 30 mg/day. 7T 31P-MRS was conducted at baseline and after 12-16 weeks of treatment. Results of 4 completers with MS and 6 with PD were available.
For key bioenergetic markers, percentage change from baseline at the end-of-study visit highly correlated with baseline levels. Whole-brain baseline NAD levels below the mean significantly increased at end-of-study visit. However, baseline NAD levels higher than the mean normalised to mean baseline levels. These dynamics were not only seen for total NAD levels (r2=0.6384; P=0.0056), but also for β-ATP (r2=0.8723; P<0.0001), and several other 31P-metabolites.
According to the authors, these observations indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics. Full analyses will be conducted once the 2 trials are completed. Another ongoing study, called VISIONARY-MS, will further explore the possible neuroprotective effects of the brain metabolic homeostasis observed with CNM-Au8 treatment.
- Ren J, et al. Effects of nanocatalysis on CNS bioenergetic markers in patients treated with CNM-Au8: Interim results from two Phase 2 31Phosphorous imaging studies. MSVirtual 2020, P0206.
« Retinoid-X receptor agonist promotes remyelination Next Article
Masitinib: a first-in-class TKI as treatment of progressive MS »
Table of Contents: MS Virtual 2020
Letter from the Editor
MS Virtual 2020 Highlights Podcast
COVID-19 and MS
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Induction therapy over treatment escalation
Intestinal IgA-producing B cells help curb CNS inflammation in MS